Bimatoprost Sustained-Release application acceptance tops weekly news highlights

Here are some of the past week’s top stories:

 

Clerio Vision acquires Hydrogel Vision

Hydrogel Vision offers the Extreme H2O product line and differentiated offerings to personalize contact lens wearing experiences, including lenses in multiple diameters. The lenses are made from a proprietary material that retains up to 99% of its moisture. Read more.

FDA rejects Etons allergic conjunctivitis drop

Eton’s partner, Bausch Health Companies, which acquired the U.S. rights to EM-100 in February, received a complete response letter from the FDA regarding the filing. Read more.

FDA accepts application for Bimatoprost Sustained-Release

Data supporting the application from the two phase 3 ARTEMIS trials showed Bimatoprost SR reduced IOP by 30% over 12 weeks. In addition, more than 80% of patients were treatment-free after three Bimatoprost SR treatments and did not require further treatment for IOP control for at least 12 months. Read more.

Altaire expands ophthalmic product recall

Altaire Pharmaceuticals is recalling prescription and over-the-counter drugs sold by OCuSOFT, as well as OTC products sold by Accutome, Focus Laboratories, Grandall Distributing Co. Inc., Prestige Brands Inc., Natural Ophthalmics and TRP Company, Inc., the company announced in press releases. Read more.

Nicox completes enrollment in NCX 470 trial

Enrollment is complete in a phase 2 clinical trial of NCX 470, Nicox’s second-generation nitric oxide-donating bimatoprost analog, for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension. Read more.

Here are some of the past week’s top stories:

 

Clerio Vision acquires Hydrogel Vision

Hydrogel Vision offers the Extreme H2O product line and differentiated offerings to personalize contact lens wearing experiences, including lenses in multiple diameters. The lenses are made from a proprietary material that retains up to 99% of its moisture. Read more.

FDA rejects Etons allergic conjunctivitis drop

Eton’s partner, Bausch Health Companies, which acquired the U.S. rights to EM-100 in February, received a complete response letter from the FDA regarding the filing. Read more.

FDA accepts application for Bimatoprost Sustained-Release

Data supporting the application from the two phase 3 ARTEMIS trials showed Bimatoprost SR reduced IOP by 30% over 12 weeks. In addition, more than 80% of patients were treatment-free after three Bimatoprost SR treatments and did not require further treatment for IOP control for at least 12 months. Read more.

Altaire expands ophthalmic product recall

Altaire Pharmaceuticals is recalling prescription and over-the-counter drugs sold by OCuSOFT, as well as OTC products sold by Accutome, Focus Laboratories, Grandall Distributing Co. Inc., Prestige Brands Inc., Natural Ophthalmics and TRP Company, Inc., the company announced in press releases. Read more.

Nicox completes enrollment in NCX 470 trial

Enrollment is complete in a phase 2 clinical trial of NCX 470, Nicox’s second-generation nitric oxide-donating bimatoprost analog, for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension. Read more.